Prenatal diagnosis of chronic granulomatous disease (CGD) in four high risk male fetuses.
Prenatal diagnosis of chronic granulomatous disease (CGD) was performed in four male high risk fetuses. The male sex was previously determined by an amniotic cell karyotype. Three kinds of test were performed on fetal blood obtained by umbilical venous puncture under fetoscopy at the 20th gestational week: nitroblue tetrazolium reduction (NBT) cytochemical test with phorbol myristate acetate (PMA) as activator; luminol enhanced chemiluminescence with activation by serum opsonized zymosan (STZ) or PMA; superoxide anion (0-2) production by measurement of the superoxide dismutase inhibitable reduction of cytochrome c with PMA as activator. Results were compared to those obtained in six fetuses investigated for other inherited diseases. In one case, absence of granulocyte defects was confirmed at birth. In three other cases, the tests showed deficient metabolic oxidative granulocytes. The pregnancy was terminated and the CGD diagnosis was confirmed on the products of abortion. The use of three different techniques performed on whole blood for CGD prenatal diagnosis is recommended instead of a single isolated test to ensure a higher confidence in the diagnosis.
D005260:Female; D005312:Fetal Blood; D005315:Fetal Diseases / Q000175:diagnosis*; D006098:Granulocytes / Q000378:metabolism*; D006105:Granulomatous Disease, Chronic / Q000175:diagnosis*; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D011247:Pregnancy; D011296:Prenatal Diagnosis; D012306:Risk